D. Boral Capital Reiterates Buy Rating for Kairos Pharma (NYSEAMERICAN:KAPA)

D. Boral Capital reissued their buy rating on shares of Kairos Pharma (NYSEAMERICAN:KAPA) in a research report report published on Thursday morning,Benzinga reports. They currently have a $9.00 price target on the stock.

Kairos Pharma Stock Performance

NYSEAMERICAN:KAPA opened at $0.98 on Thursday. Kairos Pharma has a fifty-two week low of $0.85 and a fifty-two week high of $4.00. The firm’s 50-day simple moving average is $1.35.

Kairos Pharma Company Profile

We are a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer and glioblastoma.